: Therapy with MIA - 602
significantly reduced tumor growth and enhanced the efficacy of doxorubicin in both cell lines.
Results: Therapy with MIA - 602
significantly reduced tumor growth and enhanced the efficacy of doxorubicin in both cell lines.
Not exact matches
When the researchers
reduced the amount of IL13RA2 expression in the cancer cells, they found that the
tumor growth was
significantly slower in models.
Combination therapy resulted in
significantly reduced growth compared to controls (P < 0.001), and
tumors treated with MIA - 602 (P < 0.05) or doxorubicin (P < 0.001)(figure 1b).